REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights Achieved record worldwide revenue of $20.8 million in the second quarter of 2024, a 21% increase over the same period last year and an increase of 21% on a constant currency basis Delivered $13.9 million in U.S. revenue i ...

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform, which are designed to assess and treat severe emphysema/COPD patients [2] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, recognized as a standard of care treatment option for severe emphysema [2] Product and Market - The Zephyr Valve is designated as a "breakthrough device" by the FDA, highlighting its innovative nature and potential impact on patient care [2] - The Zephyr Valve is included in global treatment guidelines, indicating its widespread acceptance and adoption in the medical community [2] Investor Relations - Pulmonx Corporation will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2024, at 5:00 AM PT / 8:00 AM ET [4] - A live and archived webcast of the presentation will be available on the "Investors" section of the Pulmonx website [1]

Core Insights - Pulmonx's existing strategy is gaining traction, with Q1 revenues of $18.9 million reflecting a 30% year-over-year growth [3][15] - The company is not expected to make significant strategic changes in the near term, focusing instead on refining its current approach [6][30] - Despite positive revenue growth, Pulmonx's operating expenses significantly exceed revenues, leading to a projected breakeven point not expected until 2026 at the earliest [16][42] Financial Performance - Pulmonx reported Q1 revenues of $18.9 million, a 30% increase compared to the previous year [3][15] - Total operating expenses for Q1 were $28.6 million, resulting in a net loss of $13.7 million, an improvement from a loss of $15.9 million in the same quarter last year [7][16] - The company has a market capitalization of $307 million and an enterprise value of $228 million, with significant stock-based compensation impacting financials [12][20] Strategic Focus - The company aims to enhance physician awareness and best practices while continuing to attract large users of its Zephyr Valve [2][25] - There is a focus on maintaining existing strategies rather than pursuing mergers and acquisitions, despite the potential for a large total addressable market [30][40] - The CEO has indicated that while the strategy may need fine-tuning, no major shifts are anticipated in the immediate future [6][28] Future Outlook - Analysts forecast conservative revenue growth, with expectations of only high teens growth rates for upcoming quarters [21][36] - The company is positioned for a potential 'beat-and-raise' quarter due to strong sales momentum against conservative estimates [36][47] - Concerns remain regarding the company's ability to sustain operations until reaching breakeven, with estimates suggesting a need for approximately $160 million in operating losses before achieving this milestone [45][46]

Core Insights - Pulmonx Corporation, a leader in minimally invasive treatments for lung disease, will release its financial results for Q2 2024 on July 31, 2024, after market close [1] - A conference call to discuss these results will be held at 1:30 p.m. PT / 4:30 p.m. ET on the same day [1] Company Overview - Pulmonx Corporation specializes in treatments for chronic obstructive pulmonary disease (COPD) and offers products such as the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform [3] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is available in over 25 countries, recognized as a standard treatment option for severe emphysema [3] - The company's products aim to improve breathing, activity levels, and quality of life for patients suffering from severe emphysema/COPD [3]

Core Viewpoint - Pulmonx Corporation (LUNG) shares have increased by 17.1% recently, with analysts suggesting a potential upside of 80.3% based on a mean price target of $15.83 [1][10]. Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $1.72, indicating variability among analysts [2]. - The lowest price target of $14 suggests a 59.5% increase, while the highest target of $18 indicates a potential surge of 105% [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [8]. Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about LUNG's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [10]. - Over the past 30 days, the Zacks Consensus Estimate for the current year has risen by 8.7%, with two estimates moving higher and no negative revisions [11]. - LUNG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [12].

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif., May 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult p ...

REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the "Compensation Committee") granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on May 6, 2024 to ...

Shares of Pulmonx Corporation (LUNG) have gained 19.2% over the past four weeks to close the last trading session at $9.82, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.33 indicates a potential upside of 56.1%.The average comprises six short-term price targets ranging from a low of $12 to a high of $18, with a standard deviation of $2.34. While the lowest estimate indicat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other jur ...

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this company would post a loss of $0.39 per share when it actually produced a loss of $0.36, delivering a surprise of 7.69%.Over the last four quarters, the company has surpa ...